Ahmed Ghanem

Ahmed Ghanem

Auto-generated profile, based on publicly available information

Ahmed Ghanem

Cardiology Department, The Lundquist Institute, Torrance, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2022 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
VMVenkat S. Manubolu
Venkat S. Manubolu
DVDhiran Verghese
Dhiran Verghese
SLSuvasini Lakshmanan
Suvasini Lakshmanan
LALuay Alalawi
Luay Alalawi
AKApril Kinninger
April Kinninger
Matthew Jay BudoffMatthew Jay Budoff
Matthew Jay Budoff

1 October 2018 in Melanoma Research
Verified
Journal Article
Closed access
AMAmr Menshawy
Amr Menshawy
AEAbdelrahman A. Eltonob
Abdelrahman A. Eltonob
SBSarah A. Barkat
Sarah A. Barkat
AGAhmed Ghanem
Ahmed Ghanem
MMMahmoud M. Mniesy
Mahmoud M. Mniesy
AEAhmed Elgebaly
Ahmed Elgebaly
Nivolumab, a completely human programmed death-1 inhibitor antibody, was first approved by the Food and Drug Administration for patients with advanced malignant melanoma resistant to other modalities of treatment. In 2015, it received approval as the first line of treatment for malignant melanoma. We aimed to synthesize evidence from published randomized-controlled trials on the safety and efficacy of nivolumab, either alone or in combination with ipilimumab, in the management of advanced unresectable melanoma. We searched the following electronic databases: PubMed, Scopus, Web of Science, and Cochrane Central. The records retrieved were screened for eligibility. Time-to-event data were pooled as Hazard ratio using the generic inverse variance method and dichotomous data were pooled as relative risk (RR) in a random-effects model. We used Review Manager 5.3 software for windows. Four unique randomized-controlled trials (five reports) with a total of 1910 patients (nivolumab group, n=1207 and control group, n=703) were included. The overall effect estimate favored nivolumab plus ipilimumab versus ipilimumab alone in terms of the objective response rate [RR: 3.58, 95% confidence interval (CI): 2.08–6.14], the complete response rate (RR: 5.93, 95% CI: 2.45–14.37), the partial response rate (RR: 2.80, 95% CI: 2.16–3.64), the stable disease rate (RR: 0.56, 95% CI: 0.41–0.76), and progression-free survival (hazard ratio: 0.67, 95% CI: 0.60–0.74). The pooled studies were homogenous. Similar results were obtained for nivolumab monotherapy versus chemotherapy comparison. Nivolumab alone or combined with ipilimumab significantly improved the overall and complete response rates compared with ipilimumab alone. In addition, nivolumab resulted in longer progression-free survival with a comparable safety profile.

16 February 2023 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
Mohamed Tarek AbuelazmMohamed Tarek Abuelazm
Mohamed Tarek Abuelazm
AGAhmed Ghanem
Ahmed Ghanem
AMAbdelrahman Mahmoud
Abdelrahman Mahmoud
ABAml Brakat
Aml Brakat
MEMohamad A. Elzeftawy
Mohamad A. Elzeftawy
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
Olokizumab (OKZ) is a novel IL-6 inhibitor that directly targets IL-6 rather than its receptor. We aim to evaluate the efficacy and safety of OKZ for patients with rheumatoid arthritis (RA) and to investigate the optimal treatment regimen. A systematic review, pairwise, and network meta-analysis synthesizing randomized controlled trials (RCTs) from WOS, CENTRAL, SCOPUS, EMBASE, and PubMed until August 31, 2022. We used the risk ratio (RR) and mean difference (MD) for dichotomous and continuous outcomes, respectively, presented with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO with ID: CRD42022358082. Five RCTs with 2277 patients were included. OKZ significantly improved the American College of Rheumatology criteria (ACR) 20 (RR: 1.97 with 95% CI [1.49, 2.58], P = 0.00001), ACR50 (RR: 3.83 with 95% CI [2.13, 6.87], P = 0.00001), ACR70 (RR: 3.83 with 95% CI [2.13, 6.87], P = 0.00001), disease activity score 28 based on C-reactive protein (DAS28-CRP) (RR: 3.91 with 95% CI [2.65, 5.79], P = 0.00001), clinical disease activity index (CDAI) (RR: 2.80 with 95% CI [1.43, 5.48], P = 0.003), and health assessment questionnaire disability index (HAQ-DI) (MD: − 0.28 with 95% CI [− 0.38, − 0.18], P = 0.00001) after 12 weeks, compared to placebo. However, OKZ was also associated with a higher incidence of any adverse events (AEs) (RR: 1.15 with 95% CI [1.06, 1.25], P = 0.0005) and AEs leading to drug discontinuation (RR: 1.86 with 95% CI [1.05, 3.29], P = 0.03). OKZ is effective and with acceptable safety profile when administrated with methotrexate in patients with RA not adequately controlled by tumor necrosis factor inhibitors; however, more large-scale RCTs are still required to investigate the optimal dosing, long-term effects, and comparative efficacy versus established biological DMARDs. Key Points• OKZ is effective especially with methotrexate in RA patients.


1 May 2021 in JACC
Verified
Journal Article
Closed access
AAAudelia Arasheben
Audelia Arasheben
AKApril Kinninger
April Kinninger
SDSuraj Dahal
Suraj Dahal
SLSuvasini Lakshmanan
Suvasini Lakshmanan
AGAhmed Ghanem
Ahmed Ghanem
Matthew Jay BudoffMatthew Jay Budoff
Matthew Jay Budoff

15 April 2022
Verified
Book Chapter
Closed access
AGAhmed K. Ghanem
Ahmed K. Ghanem
Matthew Jay BudoffMatthew Jay Budoff
Matthew Jay Budoff